Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: Comparison between clinical trials and population-based database

Journal of Oncology Pharmacy Practice

Volumn 12, Issue 4, 2006, Pages 193-199

  de Lemos, Mário L ^a   Taylor, Suzanne C ^a   Barnett, Jeff B ^a   Hu, Francis ^a   Levin, Adeera ^b   Moravan, Veronika ^a   O'Reilly, Susan E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b British Columbia Provincial Renal Agency   (Canada)

Author keywords

Biphosphonates; Breast cancer; Multiple Myeloma; Pamidronate; Renal toxicity

Indexed keywords

CREATININE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; CREATININE BLOOD LEVEL; DATA ANALYSIS; DATA BASE; DRUG COST; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; CREATININE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846247898     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206073520     Document Type: Article

References (42)

1. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-36.
2. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of biphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
3. Adami S, Zamberian N. Adverse effects of biphosphonates: a comparative review. Drug Safety 1996; 14: 158-70.
4. Buysschaert M, Cosyns JP, Barreto L, et al. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 826-29.
5. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18.
6. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-72.
7. Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002; 119: 496-99.
8. Markowitz GS, Fine PL, D'Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002; 39: 1118-22.
9. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87.
10. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200.
11. Vilimovskij A, Thuerlimann B, Berenson JR, et al. Renal safety and tolerability of 90 mg of aredia (pamidronate) administered as an intravenous 1 hour infusion: preliminary results. Proc Am Soc Clin Oncol 1999; 18: 576a (abstract 2223).
12. Tyrrell CJ, Collinson M, Madsen EL, et al. Intravenous pamidronate: infusion rate and safety. Ann Oncol 1994; 5: S27-29.
13. Tyrrell CJ. Role of pamidronate in the management of bone metastases from breast cancer results of a noncomparative multicenter phase II trial. Media Multinational Co-operative Group. Ann Oncol 1994; 5: S37-40.
14. Van Poznak CH, Ben-Porat L, Panageas K, et al. Renal safety of 1 hour infusion rate of pamidronate in patients (pts) with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: (abstract 208).
15. Janssen van Doorn K, Neyns B, Van der Niepen P, et al. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 2001; 89: 467-68.
16. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis 2002; 40: E2.
17. DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9: 545-51.
18. Dranitsaris G, Castel LD, Baladi JF, et al. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: a Canadian time and motion analysis. J Oncol Pharm Pract 2001; 7: 27-33.
19. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-21.
20. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-57.
21. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE), version 3.0. National Cancer Institute, 2003.
22. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter comparative trial. Cancer 2003; 98: 1735-44.
23. Berry DC, Knapp PR, Raynor T. Is 15 per cent very common? Informing people about the risks of medication side effects. Int J Pharm Pract 2002; 10: 145-51.
24. Berry DC, Raynor DK, Knapp P, et al. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Safety 2003; 26: 1-11.
25. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996; 313: 36-39.
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH E 9. Statistical principles for clinical trials. European Agency for the Evaluation of Medicinal Products, 1998.
27. Taylor SCM, Uyeno KT, O'Reilly SE, et al. Development of a systemic therapy costing model in a provincial oncology center. Eur J Cancer 2000; 36: S26 (abstract).
28. Taylor SCM, Chow L. Development of a pharmacoeconomics service in a provincial oncology program. Eur J Cancer 1997; 33: S31 (abstract).
29. Taylor SCM, Chow L. Development of a pharmacoeconomics service in a provincial oncology program. J Oncol Pharm Pract 1997; 3: 40 (abstract).
30. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
31. Ford JM, Flesch G, Leyvraz S, et al. In Bijvoet OLM, Lipton A eds. Influence of infusion rate on the pharmacokinetics of intravenous pamidronate (APD) in patients with bone metastases. Presented at the Fifteenth International Cancer Congress, Hamburg, Germany, August 1990. Hogrefe & Huber, 1990: 11-17.
32. Millward MJ, Simmons D, Procter M, et al. Comparison of 1-hour vs. 2-hour infusions of disodium pamidronate (APD) in breast cancer with bone metastases (abstract). Br J Cancer 1990; 62: 521-22.
33. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Media Multinational Co-operative Group. J Clin Oncol 1996; 14: 2552-59.
34. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments]. New Engl J Med 1996; 334: 488-93.
35. McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. Br Med J 1999; 319: 312-15.
36. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-62.
37. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-31.
38. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-81.
39. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98: 962-69.
40. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.
41. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-87.
42. Migliorati CA, Siegel MA, Elting LS, et al. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. [see comment]. Lancet Oncol 2006; 7: 508-14.